Type-2 fibroblast growth factor receptor antagonists - Pipeline Insight, 2022
![](/report_cover/8047/type-2-fibroblast-growth-factor-receptor-antagonists-pipeline-insight-2022_en.gif)
This report can be delivered to the clients within 3-4 Business Days
DelveInsight’s, “Type-2 fibroblast growth factor receptor antagonists - Pipeline Insight, 2022” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Type-2 fibroblast growth factor receptor antagonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Type-2 fibroblast growth factor receptor antagonists: Overview
Fibroblast growth factor 2 (FGF2) belongs to the family of fibroblast growth factors (FGFs), and is a potent inducer involved in the processes of proliferation and differentiation of a wide variety of cells derived from mesoderm and neuroectoderm. FGF2 signals through four receptor tyrosine kinases (FGF receptor 1 through FGF receptor 4) and acts in a variety of developmental processes, including angiogenesis. FGF-2 exerts both proliferative and anti-apoptotic effects in osteoblasts.
Report Highlights
This segment of the Type-2 fibroblast growth factor receptor antagonists report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Type-2 fibroblast growth factor receptor antagonists Emerging Drugs
Further product details are provided in the report……..
Type-2 fibroblast growth factor receptor antagonists: Therapeutic Assessment
This segment of the report provides insights about the different Type-2 fibroblast growth factor receptor antagonists drugs segregated based on following parameters that define the scope of the report, such as:
Type-2 fibroblast growth factor receptor antagonists: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Type-2 fibroblast growth factor receptor antagonists therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Type-2 fibroblast growth factor receptor antagonists drugs.
Type-2 fibroblast growth factor receptor antagonists Report Insights
Current Scenario and Emerging Therapies:
DelveInsight’s, “Type-2 fibroblast growth factor receptor antagonists - Pipeline Insight, 2022” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Type-2 fibroblast growth factor receptor antagonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Type-2 fibroblast growth factor receptor antagonists: Overview
Fibroblast growth factor 2 (FGF2) belongs to the family of fibroblast growth factors (FGFs), and is a potent inducer involved in the processes of proliferation and differentiation of a wide variety of cells derived from mesoderm and neuroectoderm. FGF2 signals through four receptor tyrosine kinases (FGF receptor 1 through FGF receptor 4) and acts in a variety of developmental processes, including angiogenesis. FGF-2 exerts both proliferative and anti-apoptotic effects in osteoblasts.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Type-2 fibroblast growth factor receptor antagonists R&D. The therapies under development are focused on novel approaches for Type-2 fibroblast growth factor receptor antagonists.
This segment of the Type-2 fibroblast growth factor receptor antagonists report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Type-2 fibroblast growth factor receptor antagonists Emerging Drugs
- Pemazyre (pemigatinib): Incyte Corporation
- Lenvatinib: Eisai
Further product details are provided in the report……..
Type-2 fibroblast growth factor receptor antagonists: Therapeutic Assessment
This segment of the report provides insights about the different Type-2 fibroblast growth factor receptor antagonists drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players working on Type-2 fibroblast growth factor receptor antagonists
- Phases
- Late-stage products (Phase III and
- Mid-stage products (Phase II and
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravaginal
- Oral
- Parenteral
- Subcutaneous
- Topical
- Molecule Type
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Product Type
Type-2 fibroblast growth factor receptor antagonists: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Type-2 fibroblast growth factor receptor antagonists therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Type-2 fibroblast growth factor receptor antagonists drugs.
Type-2 fibroblast growth factor receptor antagonists Report Insights
- Type-2 fibroblast growth factor receptor antagonists Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Scenario and Emerging Therapies:
- How many companies are developing Type-2 fibroblast growth factor receptor antagonists drugs?
- How many Type-2 fibroblast growth factor receptor antagonists drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Type-2 fibroblast growth factor receptor antagonists?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Type-2 fibroblast growth factor receptor antagonists therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Type-2 fibroblast growth factor receptor antagonists and their status?
- What are the key designations that have been granted to the emerging drugs?
- Eisai
- Incyte Corporation
- AiViva BioPharma
- Boehringer Ingelheim
- Bayer Healthcare
- Advenchen Laboratories
- Abbisko Therapeutics
- Avalyn Pharmaceuticals
- Debiopharm
- Eli Lilly and Company
- Hutchison MediPharma
- Servier
- Astellas Pharma
- Taiho Oncology
- Russian Pharmaceutical Technologies
- Novartis
- Lenvatinib
- Pemigatinib
- AIV 007
- Nintedanib
- Infigratinib
- Regorafenib
- RPT-835
- Lucitanib
- TAS 120
- ABSK 091
- AP02
- ASP 5878
- E 7090
- S 49076
- Zoligratinib
- LY 2874455
- HMPL 453
Introduction
Executive Summary
Type-2 fibroblast growth factor receptor antagonists: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Type-2 fibroblast growth factor receptor antagonists – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
HMPL 453: Hutchison MediPharma
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
Lenvatinib - AiViva BioPharma
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
AP02: Avalyn Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Type-2 fibroblast growth factor receptor antagonists Key Companies
Type-2 fibroblast growth factor receptor antagonists Key Products
Type-2 fibroblast growth factor receptor antagonists- Unmet Needs
Type-2 fibroblast growth factor receptor antagonists- Market Drivers and Barriers
Type-2 fibroblast growth factor receptor antagonists- Future Perspectives and Conclusion
Type-2 fibroblast growth factor receptor antagonists Analyst Views
Type-2 fibroblast growth factor receptor antagonists Key Companies
Appendix
Executive Summary
Type-2 fibroblast growth factor receptor antagonists: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Type-2 fibroblast growth factor receptor antagonists – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
HMPL 453: Hutchison MediPharma
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
Lenvatinib - AiViva BioPharma
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
AP02: Avalyn Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Type-2 fibroblast growth factor receptor antagonists Key Companies
Type-2 fibroblast growth factor receptor antagonists Key Products
Type-2 fibroblast growth factor receptor antagonists- Unmet Needs
Type-2 fibroblast growth factor receptor antagonists- Market Drivers and Barriers
Type-2 fibroblast growth factor receptor antagonists- Future Perspectives and Conclusion
Type-2 fibroblast growth factor receptor antagonists Analyst Views
Type-2 fibroblast growth factor receptor antagonists Key Companies
Appendix